ACC 22: Results from the GIPS-IV Trial | Dr Marie-Sophie De Koning & Dr Pim van der Harst

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short interview from our coverage of the ACC 22 late-breaking trials, Dr Pim van der Harst and Dr Marie-Sophie de Koning (both from University Medical Center Groningen, Groningen, NL) discuss the data from the GIPS-IV trial which investigates the safety and efficacy of the hydrogen sulfide (H2S) donor sodium thiosulfate (STS) in patients presenting with ST-segment elevation myocardial infarction (STEMI).
This involved examining the effects of STS versus placebo in terms of infarct size reduction in randomised patients (NCT02899364).

Discussion Points:
1. Study Objectives
2. Study Design and Patient Cohort
3. Study Results
4. Take-home Messages for Clinicians
5. Further Study Recommendations

Recorded remotely from ACC, Washington DC, 2022.
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.